Ambu nedjusterer
-
Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction program. Full-year 2021/22 guidance revised
- Preliminary Q3 organic revenue growth was 8%. Visualization organic growth was 0%, Anaesthesia organic growth was 14%, and Patient Monitoring & Diagnostics (PMD) organic growth was 20%.
-
Organic revenue growth of no less than 4% (previously 13%+) EBIT margin before special items of no less than 2% (previously EBIT margin 5%+)
-
-
Og økonomisk Ugebrev havde lige, jeg ved ikke hvordan, forudset en kæmpe short squeeze. Den kan de vist godt aflyse. Det ligner kurs 50..
-
Følg også med i Ambu-chatten:
-
Mener ØU havde stillet et spørgsmål, om det bliver til et squezze, men jeg læste ikke indholdet i artiklen.
Men et spørgsmål, kan aldrig blive til en forudsigelse, i min verden
og 17. juli skriver ØU, at TA muligvis skal teste 50.
Så det er nærmere en helgardering end en forudsigelse
-
Preliminary results for Q3 2021/22, current trading (July) and launch of cost reduction program. Full-year 2021/22 guidance revised
Preliminary Q3 organic revenue growth was 8%. Visualization organic growth was 0%, Anaesthesia organic growth was 14%, and Patient Monitoring & Diagnostics (PMD) organic growth was 20%.
Current trading for July, the first month of the last quarter of the financial year 2021/22, showed an organic revenue growth of 6%, significantly below expectations.
Decision to launch a cost reduction program expected to result in an annualised savings of DKK 250m from the financial year 2022/23. One-off expenses in connection with the cost reduction program of DKK 150m, the majority of which will be booked as special items in Q4 2021/22, including an inventory write-down of DKK 45m related to Ambu
aScope
Duodeno 1.5.
FY 21/22 guidance revised to organic revenue growth of no less than 4% (previously 13%+) with an EBIT margin before special items of no less than 2% (previously EBIT margin 5%+).Ambu's Chief Executive Officer, Britt Meelby Jensen, says:
"Ambu is a great company with leading capabilities in single-use endoscopy and a comprehensive, high-quality product portfolio. We have had great successes, but also challenges. I have assessed the situation with the leadership team, and it is clear that the single-use market remains very attractive, but also that it is taking longer than expected to penetrate certain segments like duodenoscopy. To strengthen our financial position and flexibility, we have decided to launch a cost reduction program. We will take a more focused approach to innovation and sales execution, while remaining deeply committed to both. We will also adjust to work in a more structured way and mature our processes. As a consequence of the decision to implement these changes, and with a challenging current trading in July, we are unfortunately making a significant reduction to our 2021/22 full-year guidance. We remain confident in the potential to build a strong and sustainable high-growth company, delivering value to our customers, the patients we serve, and our shareholders."
PRELIMINARY HIGHLIGHTS FOR Q3 2021/22
Last year's comparative figures are stated in brackets.
Revenue was DKK 1,128m (DKK 973m) based on organic growth of 8% (7%). Reported growth was 16% (3%). For the first nine months of the year, organic growth was 5% (16%), with a reported growth of 10% (11%).
Revenue in North America grew organically by 16% (32%) and in Europe by 4% (-10%), while Rest of World declined by -4% (7%). For the first nine months of the year, organic growth rates were: North America 15% (16%), Europe -3% (16%) and Rest of World -2% (11%).
Organic growth in Visualization was 0% (0%). For the first nine months of the year, organic growth in Visualization was 0% (29%). This is driven by continued strong growth in our Cystoscopy and ENT businesses, offset by a decline in bronchoscopy due to high covid comparables, increased competition in the U.S., and lower ICU admissions. In addition, we see continued slow uptake of Ambu aScope Duodeno 1.5.
Unit sales of single-use endoscopes reached 400,000 and 1,263,000 units in total for the first nine months of the year, corresponding to sales volume growth of 4% and 11%, respectively, relative to last year.
Organic growth in Anaesthesia was 14% (-1%) and 20% (44%) in Patient Monitoring & Diagnostics (PMD). For the first nine months of the year, organic growth in Anaesthesia and PMD was 7% (0%) and 14% (7%), respectively.
Gross margin for the quarter was 55.8% (62.5%). For the first nine months of the year, the gross margin was 58.2% (63.4%). The declining gross margin is due to inflationary effects on input prices at our production facilities, ramping-up production facilities in Mexico, shifts in product mix and the inventory write-off of Ambu VivaSight 2 DLT.
OPEX totalled DKK 587m (DKK 520m), corresponding to an increase of 13% due to an increase in freight costs, depreciation, amortisation and currency translation effects, primarily driven by the appreciating USD/DKK over last year.
EBIT before special items was at DKK 42m (DKK 88m), with an EBIT margin before special items of 3.7% (9.0%). For the first nine months of the year, EBIT before special items was DKK 129m (DKK 336m) with an EBIT margin before special items of 3.9% (11.2%).
Special items include one-off cost of DKK 13m (DKK 0m) associated with the change of CEO in May. For the year-to-date special items was DKK 13m (DKK 0m).
EBIT after special items for the quarter was at DKK 29m (DKK 88m) with an EBIT margin of 2.6% (9.0%), and for the year-to-date EBIT was 116m (DKK 336m) with an EBIT margin of 3.5% (11.2%).
Total net interest-bearing debt (NIBD) was DKK 1,423m (DKK 638m), corresponding to a leverage ratio of 3.5x (1.1x) 12 months of EBITDA before special items.CURRENT TRADING (JULY PERFORMANCE)
Current trading for July showed an organic revenue growth of 6%, significantly below our expectations for a rapid acceleration in Q4 as communicated with the Q2 results.COST REDUCTION PROGRAM AND ADJUSTMENT TO PRICING PRACTICES
In order to strengthen the free cash flow and improve the profitability to support future growth, it has been decided that a cost reduction program will be implemented with immediate effect. We will reduce our sales force in certain markets and reduce investment levels into innovation, where we will take a more focused approach. The sales force reductions will reflect the slower-than-expected uptake of Ambu aScope Duodeno 1.5 but maintain our ability to commercialise our full GI pipeline. In innovation, we will continue to develop and launch our previously announced Visualization pipeline in line with our ambition to be the world leader in single-use endoscopy, but will scale down select investments into future technologies and new product developments within Anaesthesia and PMD.The cost reduction program is expected to result in an annualised impact of DKK 250m pre-tax savings (thereof approximately DKK 165m CapEx) from the financial year 2022/23.
The actions announced today will correspond to a reduction of approximately 200 employees from our global workforce, subject to consultation procedures in countries where required.
In connection with the cost reduction program, Ambu expects to record pre-tax one-off charges of DKK 150m, which will be treated as special items. The majority of the charges are expected to be recorded in Q4 2021/22. The charges include DKK 50m related to severance, DKK 55m in asset write-offs related to in-progress development projects and a write-down of DKK 45m of Ambu
aScope Duodeno 1.5 inventory. The inventory write-down is linked to a decision to not launch in additional markets for now.Ambu also announces that it is adjusting its pricing practices, to reduce the level of discounts and rebates. This is expected to result in a one-time negative impact on sales equal to approximately 1 percentage point on full-year growth in 2021/22, expected in Q4 2021/22.
REVISED FY 2021/22 GUIDANCE
As a result of the above, the guidance for the 2021/22 financial year is revised to:
Organic revenue growth of no less than 4% (previously 13%+)
EBIT margin before special items of no less than 2% (previously EBIT margin 5%+)This guidance is expected to include high-single-digit organic growth in the combined Anaesthesia and PMD businesses and above 700,000 combined ENT & cystoscope units.
A conference call is held Thursday 4 August 2022, at 08:15 (CEST). The conference is broadcast live via https://live.axion.dk/ambu/220804/zGgsu82h.html. To ask questions in the Q&A session, please call one of the numbers below five minutes before the start of the conference and enter the following access code: 75723.
Denmark (toll free): +45 80886270
Denmark (toll): +45 78774197
U.K.: +44 0‑808‑101‑1183
U.S. (toll free): +1 800‑343‑1703
U.S. (toll): +1 203‑518‑9859The presentation can be downloaded after the conference at Ambu.com/presentations.
CONTACT INFORMATION
Investor relations
Nicolai Thomsen, Director, Investor Relations & Strategic Financial Planning, [email protected] / +45 2620 8047Media
Tine Bjørn Schmidt, Head of Corporate Communications, [email protected] / +45 2264 0697Ambu A/S, Baltorpbakken 13, 2750 Ballerup, Denmark, Tel. +45 7225 2000 / CVR no.: 63 64 49 19 / www.Ambu.com
Attachment:
-
Vildt at reducere forventet salgsvækst fra 14 til 4. Så voldsomt at jeg håber det på sin vis har bragt dem "foran", så de ikke ligesom skal løbe efter udviklingen, men nye og flere og flere nedjusteringer.
I øvrigt, måske jeg har skimmet nyheden for hurtigt men synes ikke jeg noget sted kan læse om en ny emission, som nogle ellers har frygtet. En slags strejf af solskin i en ordentlig tordenskylle.
-
Ambu nedjusterer forventningerne efter skuffende juli - GENT
-
Ambu/ABG: Kursmålet sænkes til 80 kr. fra 95 kr.
https://www.proinvestor.com/investornyt/861009/ambu-abg-kursmalet-saenkes-til-80-kr-fra-95-kr
-
Ambu bemærker, at man vi skrue priserne op, så det giver måske en forklaring på, at salgsvæksten rykker sig markant ned. Men at se en aktuel nulvækst i visualisering, overrasker mig, selvom nedgangen den seneste tid, har været betydelig.
Emissionen er ikke nødvendig indtil videre og med det forbehold, at jeg ikke har læst Q3 rapporten endnu. Rent strategisk, giver det ingen mening at tage en emission lige nu, dels med et stærkt negativ nyhedsflow samt dels, at det er unødvendigt
Beslutningen bliver formentligt truffet omkring slut oktober/start november, hvis der er behov.Angående din "forventede" forudsigelse af et shortsquezze af ØU, så ved alle, at det er umuligt, at forudse en tidsmæssigplacering af et squeeze, da den bygger på uforudsete nyheder og begivenheder. Det der er uforudsigeligt, er ofte svært, at forudse før det opstår. Både for dig, mig og ØU og som jeg skrev i andet indlæg, har ØU både afdækket op og ned-muligheden på kursen. Så må læseren jo selv være kritisk og vurdere, hvilket udfald man tror på.
-
Om ØU så læste jeg det som en forudsigelse om en short squeeze, og det syntes jeg var overraskende (eller man kan sige optimistisk), eftersom jeg anså aktien som ret højt prissat
-
Ok. Men en forudsigelse var det i hvert fald ikke. Både iht. overskriften samt logikken i, at ingen kan forudsige et squeeze.
Overskrifterne fra 2 artikler i juli, var således:
"Teknisk: Optræk til kæmpe short squeeze i Ambu, shortfonde i kø ved udgangen?"
og
"Teknisk: Ambu står foran næste afgørende prøve, risiko for test af kurs 50"
Overskrift 1 er afsluttet med et "?" og overskrift 2 er formuleret med "risiko".
Ingen forudsigelser, men analyse af et udfaldsrum. Ret skal være ret.
-
I realiteten kan ingen forudsige noget som helst.
Og deres "spørgsmålstegn" spiller lidt for meget ind i hvad mange håber og drømmer om, til at jeg vil kalde den helt uskyldig og klar. Men fair nok. Og i første omgang falder aktien mindre end jeg havde regnet med og det er jo godt for dem der har den.
Hav en god dag derude
-
Det hurtige svar er jo åbenlyst, at det er den aktuelle betalingsvillighed fra investoren, i det frie markedet. Du ved, udbud og efterspørgsel, der mødes i en spotpris i et effektivt marked.
-
Ambu/Sydbank: Uskøn nedjustering er knyttet til væksthåb
-
Hvad giver, at man kan anvende P/E som forudsætning, for en prissætning af en aktie?
Prisen bestemmes af hvad køber og sælger kan enes om i en handel til såkaldt dagsværdi.
Du må finde én der har købt i kurs 77 og spørge pågældende, hvorfor betalingsvilligheden er kurs 77 og om man har anvendt PE som en forudsætning.
-
Jamen det er jeg helt enig i og det er jo også derfor jeg mente, at ØU ikke skulle skydes noget i skoene, som de skulle stå på mål for, blot fordi deres budskab blev mistolket som en forudsigelse
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind